Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations
Status:
Recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well olaparib works in treating patients with glioma,
cholangiocarcinoma, or solid tumors with IDH1 or IDH2 mutations that have spread to other
places in the body (metastatic) and usually cannot be cured or controlled with treatment
(refractory). Olaparib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth.